JP2019519476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519476A5 JP2019519476A5 JP2018554702A JP2018554702A JP2019519476A5 JP 2019519476 A5 JP2019519476 A5 JP 2019519476A5 JP 2018554702 A JP2018554702 A JP 2018554702A JP 2018554702 A JP2018554702 A JP 2018554702A JP 2019519476 A5 JP2019519476 A5 JP 2019519476A5
- Authority
- JP
- Japan
- Prior art keywords
- diastereomer
- stereoisomer
- enantiomer
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCCCC[C@](CC)*[C@@](*(C)C)[C@](C1)[C@]1[C@@]1C[C@@](CCCCC)CC1 Chemical compound CCCCCC[C@](CC)*[C@@](*(C)C)[C@](C1)[C@]1[C@@]1C[C@@](CCCCC)CC1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326574P | 2016-04-22 | 2016-04-22 | |
| US62/326,574 | 2016-04-22 | ||
| PCT/US2017/028950 WO2017185036A1 (en) | 2016-04-22 | 2017-04-21 | Bifunctional molecules for degradation of egfr and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519476A JP2019519476A (ja) | 2019-07-11 |
| JP2019519476A5 true JP2019519476A5 (enExample) | 2020-05-28 |
| JP6968823B2 JP6968823B2 (ja) | 2021-11-17 |
Family
ID=60116448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554702A Active JP6968823B2 (ja) | 2016-04-22 | 2017-04-21 | Ｅｇｆｒの分解のための二官能性分子、及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10450310B2 (enExample) |
| EP (2) | EP3892272B1 (enExample) |
| JP (1) | JP6968823B2 (enExample) |
| CN (1) | CN109475528B (enExample) |
| AU (1) | AU2017254713C1 (enExample) |
| CA (1) | CA3021358A1 (enExample) |
| WO (1) | WO2017185036A1 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP2018526430A (ja) | 2015-07-10 | 2018-09-13 | アルヴィナス・インコーポレイテッド | タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法 |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| JP6968823B2 (ja) | 2016-04-22 | 2021-11-17 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｇｆｒの分解のための二官能性分子、及び使用方法 |
| JP6927999B2 (ja) * | 2016-04-22 | 2021-09-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ９（ｃｄｋ９）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ９の分解および使用法 |
| US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| AU2017367872B2 (en) * | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| CN118834201A (zh) | 2016-12-01 | 2024-10-25 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| KR20190101406A (ko) * | 2016-12-23 | 2019-08-30 | 아비나스 오퍼레이션스, 인코포레이티드 | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| KR102839545B1 (ko) | 2016-12-23 | 2025-07-29 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| CA3049912A1 (en) | 2017-01-26 | 2018-08-02 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| JP2020506922A (ja) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 |
| CN110621322A (zh) | 2017-02-08 | 2019-12-27 | 达纳-法伯癌症研究所有限公司 | 用异双功能性化合物进行的可调节的内源性蛋白质降解 |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| CN111491933A (zh) * | 2017-12-18 | 2020-08-04 | 豪夫迈·罗氏有限公司 | 具有e3泛素连接酶部分的egfr双功能抑制剂 |
| JP2021512059A (ja) | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| TW201945357A (zh) | 2018-02-05 | 2019-12-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| EP3752504A4 (en) * | 2018-02-14 | 2021-06-09 | Dana Farber Cancer Institute, Inc. | IRAQ DEGRADER AND USES THEREOF |
| EP3755330A4 (en) * | 2018-02-20 | 2021-11-24 | Dana-Farber Cancer Institute, Inc. | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND THEIR METHODS OF USE |
| WO2019183523A1 (en) * | 2018-03-23 | 2019-09-26 | Genentech, Inc. | Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl) |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| CN108610333B (zh) * | 2018-06-08 | 2020-04-03 | 绍兴文理学院 | 诱导MDM2自我降解E3泛素连接酶二聚体酰胺类小分子PROTACs |
| CN108610332B (zh) * | 2018-06-08 | 2020-04-03 | 绍兴文理学院 | 诱导MDM2自我降解E3泛素连接酶二聚体酯类小分子PROTACs |
| WO2019241231A1 (en) * | 2018-06-11 | 2019-12-19 | Abhishek Sharma | Antiestrogen compounds |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| US20210338825A1 (en) * | 2018-09-28 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Degraders of hepatitis c virus ns3/4a protein |
| AU2019381688A1 (en) | 2018-11-13 | 2021-06-03 | Biotheryx, Inc. | Substituted isoindolinones |
| US20240108747A1 (en) | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| CN110204532B (zh) * | 2019-05-15 | 2022-03-08 | 浙江工业大学 | 一种靶向egfr蛋白降解的化合物及其制备方法和应用 |
| CA3144402C (en) | 2019-06-21 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Allosteric egfr inhibitors and methods of use thereof |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| CN112321566B (zh) * | 2019-08-05 | 2022-06-10 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN119019369A (zh) | 2019-10-17 | 2024-11-26 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| JP7804576B2 (ja) * | 2019-12-16 | 2026-01-22 | 北京泰徳製薬股▲フン▼有限公司 | Ｅｇｆｒキナーゼを阻害してその分解を誘導する化合物 |
| PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
| MX2022007659A (es) | 2019-12-20 | 2022-07-19 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr). |
| WO2021152113A1 (en) * | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| CN111592535B (zh) * | 2020-06-22 | 2021-07-20 | 通化师范学院 | 一种抗egfr突变的抑制剂eai045的制备方法 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| CN114057770B (zh) * | 2020-08-06 | 2023-05-02 | 成都先导药物开发股份有限公司 | 靶向egfr蛋白降解的双功能化合物 |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| JP2023541612A (ja) * | 2020-09-11 | 2023-10-03 | ジェイツーエイチ バイオテック インコーポレイテッド | Ｅｇｆｒ突然変異癌の抑制用化合物及びその医薬用途 |
| KR20230069144A (ko) | 2020-09-14 | 2023-05-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태 |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| CN112608302B (zh) * | 2020-12-28 | 2022-05-24 | 郑州大学第一附属医院 | 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用 |
| CN113004251B (zh) * | 2021-03-05 | 2022-09-27 | 郑州大学第一附属医院 | 含2-硝基咪唑的喹唑啉类衍生物及其应用 |
| CN117337175A (zh) * | 2021-04-02 | 2024-01-02 | 密歇根大学董事会 | 癌症治疗的组合疗法 |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| US11981678B2 (en) | 2021-04-29 | 2024-05-14 | Northwestern University | Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein |
| US12042543B2 (en) | 2021-04-30 | 2024-07-23 | Northwestern University | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 |
| WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| EP4395549A1 (en) | 2021-09-01 | 2024-07-10 | Oerth Bio LLC | Compositions and methods for targeted degradation of proteins in a plant cell |
| CN115109055B (zh) * | 2022-05-26 | 2023-11-28 | 北京康辰药业股份有限公司 | 一种用于egfr降解的双功能化合物及其应用 |
| CN115160311B (zh) * | 2022-05-26 | 2024-03-15 | 北京康辰药业股份有限公司 | 一种用于egfr降解的双功能化合物及其应用 |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| CN115286643B (zh) * | 2022-09-02 | 2023-09-01 | 南京大学 | 蛋白质靶向降解化合物及其制备方法和应用 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2024086132A1 (en) * | 2022-10-17 | 2024-04-25 | Ohio University | Protacs targeting viral enzymes for precise treatment of covid-19 |
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| CN119317636A (zh) * | 2023-03-07 | 2025-01-14 | 艾博生物科技(上海)有限公司 | 编码活化EGFR突变肽的免疫调节治疗性mRNA组合物 |
| WO2024246838A1 (en) | 2023-05-31 | 2024-12-05 | Beigene Switzerland Gmbh | Compounds for the degradation of egfr kinase |
| CN121368481A (zh) * | 2023-06-29 | 2026-01-20 | 丹娜-法伯癌症研究院 | 用于降解dna甲基转移酶1 (dnmt1)的蛋白水解靶向嵌合体(protacs)的合成和体外表征 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| WO2025137613A1 (en) * | 2023-12-22 | 2025-06-26 | Ganymede Oncology, Inc. | Cycloalkylene nrf2 protein degraders |
| WO2025235298A1 (en) * | 2024-05-07 | 2025-11-13 | Nikang Therapeutics, Inc. | Bifunctional compounds containing thiazolyl derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA154303A (en) | 1913-06-27 | 1914-03-10 | Albert C. Campbell | Fire alarm |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| AU2001295041A1 (en) | 2000-09-08 | 2002-03-22 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| AU2009298877A1 (en) * | 2008-09-23 | 2010-04-08 | Georgetown University | Viral and fungal inhibitors |
| EP2588129A4 (en) | 2010-06-30 | 2014-07-09 | Univ Brandeis | ON SMALL MOLECULES TARGETED PROTEIN REMOVAL |
| CA2823837A1 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| WO2013106646A2 (en) * | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| RU2666530C2 (ru) * | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
| EP2846784A4 (en) | 2012-05-11 | 2016-03-09 | Univ Yale | COMPOUNDS FOR PROMOTING PROTEIN REMOVAL AND PROCESS THEREFOR |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP6778114B2 (ja) * | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US10201617B2 (en) | 2014-10-24 | 2019-02-12 | Zhuhai Beihai Biotech Co., Ltd. | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin |
| WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MX390189B (es) | 2015-01-20 | 2025-03-20 | Arvinas Operations Inc | COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs. |
| GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| RU2694895C2 (ru) | 2015-05-22 | 2019-07-18 | Биотерикс, Инк. | Нацеленные на белки соединения, их композиции, способы и применения |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| CA2987914C (en) | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP2018526430A (ja) | 2015-07-10 | 2018-09-13 | アルヴィナス・インコーポレイテッド | タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法 |
| WO2017011590A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| CA2994969A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017117474A1 (en) | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| CN113788818A (zh) | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| BR112018070859A2 (pt) | 2016-04-12 | 2019-02-05 | Univ Michigan Regents | degradantes da proteína de bet |
| JP6968823B2 (ja) | 2016-04-22 | 2021-11-17 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｇｆｒの分解のための二官能性分子、及び使用方法 |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CA3024556A1 (en) | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| KR20190101406A (ko) * | 2016-12-23 | 2019-08-30 | 아비나스 오퍼레이션스, 인코포레이티드 | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 |
-
2017
- 2017-04-21 JP JP2018554702A patent/JP6968823B2/ja active Active
- 2017-04-21 AU AU2017254713A patent/AU2017254713C1/en active Active
- 2017-04-21 EP EP21175006.2A patent/EP3892272B1/en active Active
- 2017-04-21 CA CA3021358A patent/CA3021358A1/en active Pending
- 2017-04-21 CN CN201780025159.0A patent/CN109475528B/zh active Active
- 2017-04-21 WO PCT/US2017/028950 patent/WO2017185036A1/en not_active Ceased
- 2017-04-21 EP EP17786758.7A patent/EP3445357B1/en active Active
-
2018
- 2018-10-17 US US16/163,254 patent/US10450310B2/en active Active
-
2019
- 2019-09-30 US US16/588,750 patent/US11161842B2/en active Active
-
2021
- 2021-09-27 US US17/449,027 patent/US20220017510A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519476A5 (enExample) | ||
| JP2019514883A5 (enExample) | ||
| JP2019514882A5 (enExample) | ||
| JP2019514876A5 (enExample) | ||
| JP2016523973A5 (enExample) | ||
| JP2019535744A5 (enExample) | ||
| CN107771078B (zh) | 用于制备抗癌剂1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)环丙胺、其结晶形式和其盐的方法 | |
| JP2019510801A5 (enExample) | ||
| JP2020536091A5 (enExample) | ||
| JP2010524896A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2022541467A (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| JP2021507900A5 (enExample) | ||
| JP2019520398A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2016053042A5 (enExample) | ||
| JP2019517475A5 (enExample) | ||
| JP2020500869A5 (enExample) | ||
| CN110573501A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP2010524899A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2004522792A5 (enExample) | ||
| JP2018501285A5 (enExample) | ||
| TW201335148A (zh) | 吡啶酮衍生物 | |
| JP2018538304A5 (enExample) |